References
- Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in parkinson’s disease. J Neural Transm (Vienna). 2008;115(3):443–460.
- Sakakibara R, Panicker J, Finazzi-Agro E, et al. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551–563.
- Sakakibara R, Tateno F, Kishi M, et al. Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis. 2012;46(3):565–571.
- Sakakibara R, Tateno F, Nagao T, et al. Bladder function of patients with Parkinson’s disease. Int J Urol. 2014;21(7):638–646.
- Hajebrahimi S, Chapple CR, Pashazadeh F, et al. Management of neurogenic bladder in patients with Parkinson’s disease: a systematic review. Neurourol Urodyn. 2019;38(1):31–62.
- Krhut J, Borovička V, Bílková K, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37(7):2226–2233.
- Reichmann H. Clinical criteria for the diagnosis of Parkinson’s disease. Neurodegener Dis. 2010;7(5):284–290.
- Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020–1028.
- Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology. 2006;68(2):318–323.
- Coyne KS, Thompson CL, Lai JS, et al. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255–263.
- Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170.
- Gotoh M, Homma Y, Yokoyama O, et al. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology. 2011;78(4):768–773.
- Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176(2):627–632.
- Walter U, Dressler D, Wolters A, et al. Overactive bladder in Parkinson’s disease: alteration of brainstem raphe detected by transcranial sonography. Eur J Neurol. 2006;13(12):1291–1297.
- Soebadi MA, Hakim L, Van der Aa F, et al. Real-life data on mirabegron in neurogenic bladder dysfunction. Urol Int. 2019;103(2):195–201.
- El Helou E, Labaki C, Chebel R, et al. The use of mirabegron in neurogenic bladder: a systematic review. World J Urol. 2020; 38(10):2435–2442.
- Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord. 2018;57:22–26.
- Gubbiotti M, Conte A, Di Stasi SM, et al. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: a pilot study. Ther Adv Neurol Disord. 2019;12:1756286419843458.
- Cho SY, Jeong SJ, Lee S, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson’s disease: a double-blind, randomized placebo-controlled trial (Parkinson’s Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn. 2021;40(1):286–294.
- Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(5):514–520.
- Yonguc T, Sefik E, Inci I, et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson’s disease. World J Urol. 2020;38(8):2013–2019.
- Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119–128.
- Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016; 69(2):311–323.